CRANBURY, N.J., Jan. 7, 2022 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a specialized
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin peptide
receptor system, announced that the Company will present and host
one-on-one meetings at the H.C. Wainwright BioConnect Virtual
Conference being held January 10–13, 2022.
Carl Spana, PhD, President and
Chief Executive Officer will provide an update on the Company's
pipeline, including the ongoing pivotal Phase 3 MELODY-1 study of
PL9643 in patients suffering from dry eye disease.
The Company's presentation will be available for on demand
listening beginning at 7:00 a.m. ET on Monday, January 10, 2022, through the H.C.
Wainwright BioConnect conference portal.
To request a one-on-one meeting with Palatin during the
conference, please contact your H.C. Wainwright representative or
email ir@palatin.com.
About Palatin
Palatin is a biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin and natriuretic peptide
receptor systems, with targeted, receptor-specific product
candidates for the treatment of diseases with significant unmet
medical need and commercial potential. Palatin's strategy is to
develop products and then form marketing collaborations with
industry leaders to maximize their commercial potential. For
additional information regarding Palatin, please visit Palatin's
website at www.palatin.com and follow Palatin on Twitter at
@PalatinTech.
Forward-looking Statements
Statements in this press
release that are not historical facts, including statements about
future expectations of Palatin, such as statements about clinical
trial plans and potential results for clinical or pre-clinical
programs, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in the
Private Securities Litigation Reform Act of 1995. Palatin intends
that such forward-looking statements be subject to the safe harbors
created thereby. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that could cause
Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating for events that
occur after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-to-present-at-hc-wainwright-bioconnect-conference-301456337.html
SOURCE Palatin Technologies, Inc.